The US Federal Trade Commission finalized an order on July 15, 2026 against a supplement seller and two officers over allegedly deceptive growth claims and employee or incentivized reviews. Across markets, an endorsement does not supply evidence for a food claim, and responsibility depends on who controlled, created or distributed the message.
A July 2026 review found only low- or very-low-certainty evidence for exosome-based nonsurgical facial rejuvenation. Evidence for products labeled with exosomes, NAD+, stem cells or peptides depends on the formulation, route and outcome, not the laboratory term alone.
World Medical Association guidance reaffirmed in October 2024 tells physicians to give evidence-based information and avoid recommending unproven products in media. A doctor's appearance, a ‘clinically proven’ label and a patent answer different questions, and none alone establishes a supplement's claimed effect.
The European Union's 2024 annual report said a screening found that 97 percent of the influencers checked posted commercial content, but only one in five consistently identified it as advertising. For supplement posts, a sponsorship label identifies a commercial tie; it does not show that a health claim matches regulator records or human evidence.
Codex Alimentarius guidance treats “natural” and absence claims as conditional marketing claims, not proof that a packaged food is safer or more nutritious. The ingredient list provides more specific evidence, but national rules determine how each claim and additive must be declared.
European food-safety assessors said in 2025 that available evidence still could not establish a safe daily intake of monacolins from red yeast rice supplements. Monacolin K is structurally identical to lovastatin, and products may vary in strength and contamination risk.
The World Gastroenterology Organisation's 2023 guideline says probiotic benefits should be tied to a named strain or strain combination at an effective dose. A large CFU count alone cannot show that a product matches the evidence or will remain potent through its shelf life.
The AREDS2 primary analysis did not show that adding lutein and zeaxanthin reduced progression to late age-related macular degeneration. Later findings apply to people who already had intermediate disease or late disease in one eye, not to healthy screen users.
A 2026 evidence review found that oral NMN changes NAD-related biomarkers, while its effects on health and physical function remain inconsistent. Taiwan also bars food advertising from claiming medical efficacy, making product legality a separate question from clinical benefit.
